Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Professor Steve Myers, Non-Executive Director of the Company, has purchased today a total of 400,000 ordinary shares of 25 pence in the Company at a price of 26 pence per Ordinary Share.
Following this transaction, Professor Myers holds 450,569 Ordinary Shares, representing 0.59% of the Company’s issued capital.
|
Advanced Oncotherapy Plc |
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 20 3617 8728 |
|
Nicolas Serandour, CEO |
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
Stifel Nicolaus Europe (Joint Broker) |
|
|
Jonathan Senior / Ben Maddison |
Tel: +44 20 7710 7600 |
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
|
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |